JIANMIN GROUP(SH:600976) Chang Jiang Ri Bao·2026-01-13 01:00Group 1 - The National Medical Products Administration announced the approval of three Class I innovative drugs from Wuhan, marking the city's best historical performance in original drug innovation and research [1] - The approved drugs are classified as "global firsts" or "fill market gaps," highlighting their significance in the pharmaceutical industry [2] - The first drug, "Recombinant Human Albumin Injection (Rice)," developed by Wuhan Heyuan Biotechnology Co., utilizes genetic engineering to produce human-like albumin from rice, effectively turning rice into a "blood bank" [2] Group 2 - The second drug, "Children's Cow Bile Heat-Reducing Patch," developed by Jianmin Pharmaceutical Group, is the only approved traditional Chinese medicine gel patch for children in the last 20 years, filling a clinical gap in pediatric fever treatment [2] - The third drug, "Oral Hexavalent Recombined Rotavirus Live Attenuated Vaccine," developed by Wuhan Institute of Biological Products, is the world's first hexavalent rotavirus vaccine, capable of preventing six types of rotavirus-induced diarrhea, breaking the long-standing monopoly of foreign companies [2]